HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9 Abstract Purpose: e histone deacetylase (HDAC) inhibitor trichostatin A (TSA) has been shown to act as an anti-tumor agent; however, the e ect and mechanism of TSA on the invasion of esophageal squamous cell carcinoma (ESCC) remains unknown.
Esophageal squamous cell carcinoma (ESCC) is the most common malignant tumor of the digestive system. A high incidence of ESCC is mainly aggregated in northern China (especially in the Henan and Shanxi provinces), South Asia and Africa [1, 2] . As one of major causes of cancer mortality in China, despite advances in multimodality therapy, the prognosis for patients with ESCC remains poor with 5-year survival rates generally below 10%. e most important reason for poor survival rate is that patients with early-stage cancers are asymptomatic; most patients are diagnosed at the late stages and tumor invasion and metastasis are the major causes of death [3, 4] . e etiology of ESCC has been shown to be multifactorial including environmental and genetic factors [5] and the mechanism of ESCC has not yet been elucidated. To further improve survival rate and prognosis of patients with ESCC, novel diagnostic, therapeutic and molecular prognostic markers must be developed.
Cancer is a pathologic condition related to abnormal genetic and epigenetic events that result in neoplastic transformation [6] . Histone deacetylases (HDACs) are enzymes regulating expression of genes that are associated with various signaling pathways that in uence multiple stages of tumorigenesis. By removing the acetylation of histones at active genes and modulating the acetylation of other nuclear proteins, HDACs have emerged as important targets for repressing the cellular processes and reversing the aberrant epigenetic changes associated with cancer [7, 8] . As an important type of HDAC, histone deacetylase 2 (HDAC2) has been found to be signicantly overexpressed in several tumor types [9, 10] . Abundant evidence indicates that HDAC2 plays a crucial role in the control of cell di erentiation, survival and migration [7] [8] [9] [10] . Furthermore, HDAC2 can indirectly regulate the composition of the extracellular matrix and the levels of signaling mediators [11] . Abnormal expression of HDAC2 correlates with poor prognosis in many cancer cases [10, 12, 13] . Taken together, these studies indicate that HDAC2 is a promising potential target for tumor diagnosis and therapy.
e histone deacetylase inhibitor, trichostatin A (TSA), is an antifungal antibiotic that noncompetitively inhibits HDAC in cultured mammalian cells, even at low concentrations [14, 15] . Recently, TSA has been demonstrated to exert strong anti-neoplastic e ects in vitro and in vi o by inhibiting cell invasion and metastasis as well as suppressing tumor angiogenesis [16] . It is proving useful for cancer prevention by reactivating the expression of the epigenetically silenced genes involved in invasion and metastasis [17] . Although TSA e ectively inhibit invasion of cells in culture [18] , the antimetastasis e cacy and mechanism of TSA in ESCC cell remain to be elucidated.
In the present study, immunohistochemistry and Western blot analyses were used to compare HDAC2 expression in ESCC and adjacent non-tumor tissues. To further characterize whether anti-invasion e ect of TSA is mediated through downregulation of HDAC2 and MMP2/9 expression, invasion assay and Western blot were performed using HDAC siRNA and MMP2/9 inhibitorIII in an ESCC cell line.
Materials and Methods

Tissue Samples
Fresh tissues of esophageal squamous cell carcinoma were obtained from six patients who underwent surgery at e First A liated Hospital of Zhengzhou University (Zhengzhou, China). Written informed consent to participate in the study was obtained from each patient before surgery, according to the ethical guidelines of our university. None of patients had received chemotherapy, radiotherapy and immunotherapy before surgery. Both tumor and adjacent non-tumor tissues were sampled, as con rmed by pathological examination, and each specimen was approximate 1 cm 3 in size.
Western blot analysis
Western blotting was performed according to the methods described previously [19] . Cell homogenates were prepared, 20-30 µg of proteins were fractionated by SDS-PAGE, and transferred to nitrocellulose membrane, then incubated with speci c antibodies. All antibodies were from Santa Cruz Biotech, Inc. (Santa Cruz, CA, USA). Films were digitized and densitometry was performed using an imaging analysis system (Gelpro; Media Cybernetics, Silver Spring, MD, USA).
Immunohistochemistry
All the specimens were xed in paraformaldehyde and embedded in para n. All procedures were performed according to previously described methods [19] . Para n-embedded sections (thickness, 4 µm) of tissues were depara nized in xylene and rehydrated in a graded series of mixtures of ethyl alcohol and water. Sections were microwaved in citrate bu er to extract antigens. Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide/methanol for 10 min. Sections were incubated with blocking solution and the primary antibody HDAC2 (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4ºC. A er washing with phosphate-bu ered saline, sections were incubated with biotin-labeled secondary Author et al. Running title antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 10 min and then incubated in streptavidin peroxidase for 10 min. A diaminobenzidine (DAB) kit (Sigma Diagnostics, St Louis, MO, USA) was used to detect chromogens. e primary antibodies were replaced with PBS for a negative control. Tissue sections were then counterstained with hematoxylin, dehydrated and mounted.
Cell culture and small-interfering RNA e human ESCC cell line, EC9706, were obtained from the American Type Culture Collection (Manassas, VA, USA). EC9706 cells were grown in RPMI-1640 medium (Gibco, Grand Island, NY, USA). All media were supplemented with 10% fetal bovine serum (PAA, Laboratories, Pasching, Germany). ese cells were maintained in a humidi ed 37ºC incubator with 5% CO2, fed every three days with complete medium, and subcultured when con uence was reached. Both designed siRNAs for HDAC2 and non-targeting control siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) were used for the study. EC9706 cells with 90% con uence were cultured in RPMI-1640 medium without any antibiotics overnight at 37ºC in 5% CO 2 and then transfected with HDAC2 siRNA using Lipofectamine TM 2000 (Invitrogen Co., Carlsbad, CA, USA). A er 4-6 h, RPMI-1640-containing 10% FBS was added to each well and the cells were cultured for an additional 24-72 h. A er 48 h, cells were transfected with or without HDAC2 siRNA.
Cell In asion Assay
Tumor cell invasion was performed in Matrigel-coated Boyden chamber (BD Biosciences, San Jose, CA, USA). HDACs inhibitor TSA was purchased from Sigma. MMP2/9 inhibitor III was obtained from EMD Biosciences. Brie y, cells transfected with siRNAs (scrambled or HDAC2 siRNA) were trypsinized and seeded onto the upper compartment of an invasion chamber coated with Matrigel. e lower compartment was lled with complete medium. A er an incubation period of 16 h at 37ºC, the lters were removed. Cells that had invaded onto the bottom of the inserts were xed, stained and counted under a microscope. e average number of invading cells per microscopic eld over the random ve elds was counted in each assay from four independent experiments. e same assay was performed to determine the e ects of TSA and MMP2/9 inhibitor III on the ESCC cell invasion.
Statistical analysis
Data are expressed as mean ± standard deviation. One-way ANOVA followed by the Dunnett's multiple comparison post hoc test or the unpaired Student's t-test were used for statistical analyses using GraphPad Prism so ware (GraphPad So ware Inc., San Diego, CA, USA).
Results
Upregulation of HDAC2 in ESCC
Western blot was used to detect HDAC2 expression in six ESCC tissues and adjacent non-tumor tissues.
e results showed that protein levels of HDAC2 in ESCC tissues were signi cantly higher than adjacent tissues (Fig.1) . According to the sections detected by immunohistochemistry, positive reddish staining for HDAC2 was observed in ESCC, which is mainly localized in the cytoplasm (Fig.2) . Also, weak positive staining was observed in the normal tissue. No staining was observed in the IgG control. 
HDAC2 siRNA , TSA and MMP2/9 inhibitor III induce inhibition of ESCC cells in asion
Western blotting showed human ESCC cell lines EC9706 expressed abundant endogenous HDAC2 (Fig. 3) . To determine whether HDAC2 is involved in invasion of ESCC cells, HDAC2 siRNA was used to suppress endogenous HDAC2 expression and invasion assay to investigate invasion ability in vitro. Western blot and time-course experiments demonstrated that the expression of HDAC2 in EC9706 cells was inhibited at 24, 48 and 72 h a er siRNA transfection (Fig. 3) . TSA (500 ng/ml) was signi cantly inhibited HDAC2 expression a er 48 h of treatment. For the invasion assay, cells were cultured in the complete growth media in presence of Scrambled siRNA control, HDAC2 siRNA, HDAC inhibitor TSA (500 ng/ml), MMP2/9 inhibitor III (50 μM) and DMSO control for 48 h FIGURE 4 NEAR HERE (Fig. 4) . Results showed that the numbers of invaded cells were markedly decreased in HDAC2 siRNA, TSA and MMP2/9 inhibitor III groups compared with scrambled siRNA and DMSO control groups (p <0.05) (Fig. 4) .
Downregulation of HDAC2 induces reduction of MMP-2 and MMP-9 protein expression in ESCC cells
Cells were treated with HDAC2 siRNA for 0-72 h. Western blot analysis detected that expression of MMP-2 and MMP-9 were both remarkably reduced a er 48 and 72 h transfection FIGURE 5 NEAR HERE (Fig. 5) . Meanwhile, TSA also decreased MMP-2 and MMP-9 protein levels a er 48 h treatment.
Discussion
In this study, HDAC2 was demonstrated to be over-expressed in ESCC; down-regulation of HDAC2 expression prevented cell invasion, possibly by decreasing MMP-2 and MMP-9 expression, indicating that HDAC2 may be involved in ESCC tumorigenesis. HDAC inhibitor TSA was also demonstrated to inhibit ESCC cell invasion. ese results have provided an experimental basis for identifying a potential target of ESCC therapy, especially therapy associated with ESCC metastasis. HDAC2 is a class of cellular proteases belonging to a family of 11 zinc-dependent human HDACs that are ubiquitously expressed. Under normal circumstances, HDAC2 removes acetyl groups from histones, inducing chromatin condensation and transcriptional repression [20] . Acetylation and deacetylation of histones emerge as critical aspects of an epigenetic indexing system demarcating transcriptionally active chromatin domains. e balance between acetylation and deacetylation controls several physiological and pathological cellular processes [21] . Overexpression of HDAC leads to enhancement of deacetylase activity and silencing of tumor-suppressor genes [22] . HDAC2 has been found to be signi cantly overexpressed in several tumor types, such as gastric cancer, prostate cancer and renal cancer, and the overexpressed HDAC2 usually correlated with malignant phenotype and a poor prognosis in human tumors [9, 10] . In this study, HDAC2 was shown to be overexpressed in ESCC and mainly localized in the cytoplasm. e alteration of HDAC2 expression may epigenetically mediate gene silencing in ESCC tumorigenesis.
Invasion and metastasis in cancer has been the target of intense research. Invasion is considered to be a prerequisite to metastasis, which is a pathogenic cell migration through tissues and vessels [23] . Abundant evidence indicates that the high invasion ability of ESCC is one of important reasons for poor survival rates and prognosis [7, 24] . Invasive cancer results in cell death through the formation of a tumor microenvironment that encourages tumor growth, progression and local immunosuppression [25] . Overexpressed HDAC2 may correlate with . E ects of HDAC2 siRNA, TSA and MMP2/9 speci c inhibitor on ESCC cell invasion. Cells were transfected with HDAC2 siRNA (scrambled siRNA as negative control) or treated with TSA, MMP2/9 inhibitor III(DMSO as negative control) for 48 h, then cells were subjected to invasion assay. A er 16 h, the number of invaded cells were stained and counted using the MetaMorph image analysis program. uanti ed data are expressed as means ± SEM (n=3). * p < 0.05, compared with scrambled siRNA or DMSO control, respectively. FIGURE 5. E ects of HDAC2 siRNA and TSA on MMP-2 and MMP-9 protein expression in the ESCC cell line. Cells were treated with HDAC2 siRNA and TSA for various times. Protein levels of MMP-2 and MMP-9 were then subjected to Western blot analysis. GAPDH served as a loading control. uanti ed data are expressed as means ± SEM (n=4). * , # p < 0.05, MMP-2 and MMP-9 protein levels compared with scrambled siRNA controls.
invasion and poor prognosis in human tumors; for example, cells stably overexpressing HDAC2 retain Hypoxia-Inducible Factor 1 alpha (HIF-1alpha) protein modi cations and lead to an increase in cell invasion ability in oral cancer progression [26] . Moreover, knockdown of HDAC2 expression resulted in a decrease in liver cancer cell invasion and progression [27] . Over-expression of HDAC2 decreased P53 expression and enhanced tumor cell invasion in the setting of drug resistance conferred by cancer/testis antigen CAGE [28] . ese ndings suggest a possible link between the tumor cell invasion potential and the prevalent expression of HDAC2. In this study, downregulation of HDAC2 markedly reduced the invasion of ESCC cells, consistent with previously published studies. ese data imply that HDAC2 may be considered as a major regulator of ESCC metastasis.
Degradation or breakdown of the extracellular matrix surrounding tumor cells is a functional prerequisite for invasion and metastasis. e matrix metalloproteinases (MMPs) are a family of structurally related and zinc-dependent enzymes that degrade essentially all components of extracellular matrix [29, 30] . MMP-2 and MMP-9, which are associated with the disruption of basement membrane, have an important role in tumor invasion and metastasis. ere is considerable evidence to indicate that the expressions of MMP-2 and MMP-9 in ESCC are signi cantly associated with the tumor invasion depth, tumor-node-metastasis stages, and lymph node metastasis [30] [31] [32] . ESCC, with high MMP-9, has a high malignant tendency [31, 32] . In this study, HDAC2 downregulation resulted in a decrease in MMP-2 and MMP-9 protein levels.
ese decreases indicate that HDAC2 may play a key role in ESCC metastasis through MMP-2 and MMP-9 and serve as a novel target for ESCC therapy. is hypothesis was further supported in the current study by the MMP2/9 speci c inhibitor-induced e ect on ESCC invasion. In addition, MMPs expression started to decline a er 48 h of transfection but not at 24 h when HDAC2 expression was at its lowest levels. is implies that complex signaling pathways are involved in the regulation of HDAC2-induced MMP expression and that other molecules may also participate in HDAC2-mediated ESCC cell invasion and metastasis. Previous studies have shown that downregulation of HDAC blocked cancer cell invasion and migration through MMP [32] . Many signaling pathways were involved in MMPs transcription, such as MAPKs and AP-1 [33, 34] . Another research group found that knockdown of HDAC2 enhanced p53-dependent NF-κB signaling pathways repression [11] . ose signaling pathways may also be involved in our case.
TSA is a non-speci c HDAC inhibitor, and is a potential candidate for anticancer therapy. It has been proposed that TSA's main mechanism of inhibition is to mimic the substrate and block the catalytic reaction by chelating a zinc ion in the active-site pocket through its hydroxamic acid group [35] . Recently, TSA has been shown to suppress cell invasion in various cancer cells at low concentrations. TSA treatment increased histone acetylation in the promoters and induced the expression of genes that are suppressors of invasion and metastasis, including tissue inhibitors of metalloproteinase and nm23H1/ H2 in gastrointestinal carcinogenesis. TSA suppressed invasion through metalloproteinase such as MMP-2 and MMP-9 [36, 37] . Furthermore, TSA reduced PLC-gamma 1 mRNA stability in MCF-7 breast cancer cells and this inhibited malignant cell motility [38] . In the present study, TSA signi cantly inhibited ESCC cell invasion. Importantly, cell invasion was inhibited by approximately 75% in the TSA treatment group as well as the HDAC2 siRNA group. is observation indicates that the cancer invasive inhibitory e ect of TSA is mediated through suppression of HDAC2 expression and activation, and that the reduction of MMP-2 and MMP-9 expression may mediate the invasive inhibitory e ect of TSA.
In conclusion, this study demonstrated that HDAC2 is overexpressed in ESCC and that downregulation of HDAC2 leads to the suppression of tumor invasion, indicating that HDAC2 is a key molecule in ESCC invasion. It is conceivable that HDAC2 may serve both as a predictor of the prognosis of the patients with ESCC and as a novel target for ESCC therapy. Since TSA is a HDAC inhibitor and signi cantly suppresses ESCC cell invasion, TSA could potential be used as a therapeutic against tumor invasion. For this purpose, more detailed mechanistic and functional studies on TSA are crucial.
